VOR Stock Summary and Trading Ideas (Vor Biopharma | NASDAQ:VOR)

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Vor Biopharma trades on the NASDAQ stock market under the symbol VOR.

As of September 10, 2026, VOR stock price declined to $22.34 with 650,932 million shares trading.

VOR has a beta of 2.35, meaning it tends to be more sensitive to market movements. VOR has a correlation of 0.05 to the broad based SPY ETF.

VOR has a market cap of $1.32 billion. This is considered a Small Cap stock.

In the last 3 years, VOR traded as high as $65.80 and as low as $2.62.

The top ETF exchange traded funds that VOR belongs to (by Net Assets): XBI, VTI, VXF, VTWO, FESM.

VOR has underperformed the market in the last year with a price return of -37.9% while the SPY ETF gained +17.3%. However, in the short term, VOR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +71.8% vs +4.7% return in SPY. But in the last 2 weeks, VOR shares have been beat by the market, returning -5.1% compared to an SPY return of -1.7%.

VOR support price is $22.36 and resistance is $24.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VOR shares will trade within this expected range on the day.